When insurance delays mean poorer prognosis
Mikkael Sekeres, MD, MS, shares a story illustrating that even when patients, doctors and health systems emphasize time to treat, insurance processes can delay treatment. He writes:
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“But I wondered whether the delays in his treatment hadn’t worsened his chance of being cured. I understand that, particularly in this age of breathtakingly expensive cancer treatment, there is a need for checks and balances on our treatment recommendations and their potential benefit. That public health perspective seemed awfully shortsighted, though, when I had to face my patient and his dad each week as his leukemia threatened to come raging back.”
Read the entire New York Times column.
Dr. Sekeres is Director of Cleveland Clinic Cancer Center’s Leukemia Program.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients